The marketing rights being sold to Xantis Pharma include “a wide range of products covering cardiovascular, pain management, urology and sexual health indications,” said Jeremy Drummond, sales and marketing director at Saneca.
“These are generic products that Saneca has developed and registered in East European markets,” he told in-pharmatechnologist.com.
The deal will also see the contract development and manufacturing organisation (CDMO) enter into an exclusive five-year agreement to make the products for Xantis.
“This deal is about giving the products the best chance of success in the market,” Drummond told us. “Saneca is primarily a CDMO whose expertise is in manufacturing. Xantis is a rapidly growing pharmaceutical company with a strong knowledge of East European markets.”
He added demand for the products will grow much more rapidly with Xantis’s marketing expertise, while Saneca will be able to focus on efficient manufacture and completing the development of a further nine products which the two firms have committed to work on over the next three years.
Saneca has a tablets, liquids and semi-solid drug manufacturing site in Hlohovec, Slovakia which has the capacity to manufacture over 4 billion pills per year.
“All the products will be made at this site,” said Drummond. “There is no need for additional investment to manufacture these products.”